CVE-2026-67558 Quanovate Tech Inc. (operating as Mira / Mira Care) CVE debrief

Who should care

Healthcare organizations, medical device manufacturers, and users of the Mira hormone analyzer and its Android companion app should be aware of this vulnerability and take necessary precautions to mitigate the risk.

Technical summary

The Mira Android companion app v4.5.15.4 is vulnerable to attacks due to its insecure BLE pairing mechanism. The app identifies the paired Mira hormone analyzer using a substring match against the BLE advertisement name, without implementing cryptographic peripheral authentication, MAC allowlisting, or bonded-identity checks. This weakness allows an attacker to capture live session token information and inject forged hormone measurements into the victim's cloud record and clinical trend view.

Defensive priority

High-priority defensive actions are required to address the vulnerability in the Mira Android companion app, which could allow attackers to inject forged hormone measurements into a victim's cloud record and clinical trend view.

Recommended defensive actions

• Verify the authenticity of BLE advertisements from the Mira hormone analyzer
• Implement cryptographic peripheral authentication and MAC allowlisting
• Conduct bonded-identity checks for paired devices
• Monitor for suspicious activity in cloud records and clinical trend views
• Apply vendor remediation when available

Evidence notes

Evidence is based on official CVE Program and NVD records, as well as references from ICS-CERT. However, details about the affected product, such as the vendor and product names, are not provided, limiting the scope of the debrief.

Sources and references

Methodology and review provenance

AI-assisted synthesis based on stored public vulnerability evidence. System validation, approval state, and publication status do not by themselves establish human review of this revision. PatchSiren helps prioritize defensive review and does not prove exposure or remediation on any system.